The Impact of Payer Coverage and Reimbursement Policies on Off-Label Use of Anticancer Therapies: Oncology Issues: Vol 21, No 1

Views

CrossRef citations to date

Altmetric

Click to increase image sizeClick to decrease image size

Additional information

Notes on contributors

P. Jane Totten

P. Jane Totten, BA, is an associate at Covance Market Access Services in Gaithersburg, MD, and Thomas F. Goss, PharmD, is vice president of Consulting Services at Covance Market Access Services Inc., in Gaithersburg, MD.

Thomas F. Goss

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

The Impact of Payer Coverage and Reimbursement Policies on Off-Label Use of Anticancer Therapies

Notes on contributors

P. Jane Totten

Thomas F. Goss

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

The Impact of Payer Coverage and Reimbursement Policies on Off-Label Use of Anticancer Therapies

Additional information

Notes on contributors

P. Jane Totten

Thomas F. Goss

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date